Combining SX-682 with standard treatments for relapsed or refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I trial evaluates the safety and side effects of SX-682 when used alongside standard treatments such as carfilzomib, daratumumab-hyaluronidase, and dexamethasone in patients with relapsed or refractory multiple myeloma. SX-682 is designed to enhance the immune system's ability to target and destroy tumor cells by blocking specific sites that suppress immune function. The study aims to determine how well this combination works and to assess any potential side effects in participants. Patients will be monitored for measurable disease and must have received at least one prior line of therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed relapsed/ refractory multiple myeloma
* Measurable disease including at least one of the following criteria:

  * Serum M-protein ≥ 0.5 g/dL
  * Urine M-protein ≥ 200 mg/24h
  * Serum free light chain assay: involved free light chain (FLC) level greater or equal to 100 mg/L provided serum free light chain ratio is abnormal
  * Bone marrow plasma cells ≥ 10% total bone marrow cells
* ≥ 1 prior line of therapy
* Planned treatment with a carfilzomib/daratumumab/dexamethasone regimen
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Absolute neutrophil count: ≥ 1.5 x 10\^9/L
* Platelets: ≥ 75 x 10\^9/L
* Hemoglobin: ≥ 7 g/dL
* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome
* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]) / alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \[SGPT\]): ≤ 3 x ULN
* Renal Function: Estimated creatinine clearance ≥ 45 mL/min (Cockroft-Gault)
* Left ventricular ejection fraction of at least 50%
* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months following the last dose of the investigational drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
* Participant must understand the investigational nature of this study and sign an Independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

* Patients with non-secretory myeloma, systemic light chain amyloidosis or, plasmacytoma
* Intolerance to SX-682 or any other of the treatment components
* Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)
* Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)
* Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4, or (b) QT prolonging as defined in the drug's approved label, with the exception of drugs that are considered absolutely essential for the care of the subject or if the investigator believes that beginning therapy with such medication is vital to an individual subject's care while on study, and in either case, there is no alternative medication
* Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval \> 470 msec or patients with congenital long QT syndrome
* Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure in the last 6 months
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, class III or IV heart failure (New York Heart Association functional classification system) or psychiatric illness/social situations that would limit compliance with study requirements
* History of hepatitis B, C or HIV
* Known active bacillus tuberculosis infection
* Pregnant or nursing female participants
* Unwilling or unable to follow protocol requirements
* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Where it's running

• Roswell Park Comprehensive Cancer Center
  Buffalo, New York, United States Recruiting

Study contacts

• Principal investigator: Jens Hillengass, MD — Roswell Park
• Study coordinator: Ask Rpci
• Email: askrpcil@roswellpark.org
• Phone: 1-877-275-7724

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers

  A brain-training program given before and after CAR-T therapy is tested to see if it helps cognitive and neurological outcomes for adults with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07609030

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• FT836 CAR T-cell Therapy with Daratumumab in relapsed/refractory multiple myeloma

  This phase 1 study tests whether FT836 CAR T cells given with daratumumab are safe and show early signs of activity in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07221032

• Response-based lowering of linvoseltamab doses for relapsed or refractory multiple myeloma

  This trial tests whether lowering linvoseltamab doses for people with relapsed or refractory multiple myeloma can control the cancer while reducing side effects.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07181941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.